Endonovo Therapeutics (OTCQB: ENDV), an innovative biotechnology company, recently entered an agreement to distribute its SofPulse, an easy-to-place, noninvasive device delivering pulsed electromagnetic frequencies to enhance postsurgical recovery, to Veterans Administration facilities and Department of Defense health care facilities. An article further discussing the company reads, “The long-term agreement recently signed with Veterans Healthcare Supply Solutions Inc. (“VHSS”) to directly distribute SofPulse devices to Veterans Administration facilities and Department of Defense health care facilities extends beyond traditional distribution methods, Endonovo CEO Alan Collier said in a news release (http://nnw.fm/0nEHv). . . . ‘The team at VHSS have streamlined and improved the sales, marketing and distribution of medical devices to VA and DoD facilities. VHSS is a true leader in the space, and we are thrilled to have the capacity to support their mission,’ Collier stated in a news release. ‘This agreement, which includes direct delivery to all medical facilities, extends beyond traditional distribution and includes access to their 900 federal contract officers as well as their distribution center with a state-of-the-art ERP and WMS systems.’”
To view the full article, visit http://nnw.fm/Z0zAx
About Endonovo Therapeutics Inc.
Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable electroceuticals(TM) therapeutic devices. The company’s current portfolio of commercial and clinical-stage wearable electroceuticals therapeutic devices addresses wound healing, pain, postsurgical pain and edema, cardiovascular disease, chronic kidney disease and central nervous system (“CNS”) disorders, including traumatic brain injury (“TBI”), acute concussions, postconcussion syndrome and multiple sclerosis. The company’s noninvasive electroceutical therapeutic device, SofPulse(R), using pulsed short-wave radiofrequency at 27.12 MHz, has been FDA cleared and CE marked for the palliative treatment of soft-tissue injuries and postoperative pain and edema, and has CMS national coverage for the treatment of chronic wounds. The company’s current portfolio of preclinical-stage electroceuticals therapeutic devices address chronic kidney disease, liver disease nonalcoholic steatohepatitis (“NASH”), cardiovascular and peripheral artery disease (“PAD”), and ischemic stroke. The company’s noninvasive, wearable electroceuticals therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth-factor cascades necessary for healing to occur. For more information, visit the company’s website at www.Endonovo.com.
NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://nnw.fm/ENDV
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com